查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1982557

2026-2034年全球視網膜色素變性治療市場規模、佔有率、趨勢和成長分析報告

Global Retinitis Pigmentosa Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計視網膜色素變性治療的市場規模將從 2025 年的 141.4 億美元成長到 2034 年的 252.8 億美元，2026 年至 2034 年的複合年成長率為 6.67%。

隨著對這種罕見遺傳性眼科疾病的研究不斷深入，視網膜色素變性治療的全球市場日益受到關注。視網膜色素變性會逐漸損害視網膜，導致進行性性視力喪失。人們對這種罕見疾病的認知不斷提高，診斷技術的進步也使得更多患者被發現，促使醫療專業人員和研究人員致力於開發有效的治療方法。

多種因素正在推動視網膜色素變性治療市場的發展。對基因研究和生物技術投入的增加，促進了基因療法和先進治療方法的探索。此外，政府對罕見疾病研究的支持，以及製藥公司與研究機構之間的合作，也加速了視網膜疾病創新治療方法的研發。

隨著科學進步不斷改善治療方法，市場預計將持續成長。基因編輯、幹細胞療法和視網膜植入等新興技術有望為控制或延緩疾病進展提供新的可能性。隨著研究的不斷深入和臨床試驗的不斷擴大，視網膜色素變性治療市場有望在未來幾年取得顯著進展。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球視網膜色素變性治療市場：依類型分類

  • 市場分析、洞察與預測
  • 體染色體隱性遺傳
  • 體染色體顯性遺傳
  • X連鎖

第5章 全球視網膜色素變性治療市場：依治療方式分類

  • 市場分析、洞察與預測
  • 製藥
  • 醫療設備
  • 外科手術

第6章：全球視網膜色素變性治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 局部行政部門
  • 其他

第7章 全球視網膜色素變性治療市場：依最終使用者分類

  • 市場分析、洞察與預測
  • 醫院
  • 居家照護
  • 專科診所
  • 眼科醫生
  • 其他

第8章 全球視網膜色素變性治療市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章 全球視網膜色素變性治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Johnson & Johnson Services Inc
    • Astellas Pharma Inc
    • Ionis Pharmaceuticals Inc
    • MeiraGTx Limited
    • Agtc
    • Spark Therapeutics Inc
    • Genethon
    • GenSight Biologics
    • ProQR Therapeutics
    • ReNeuron Group Plc
    • Ocugen Inc
    • Caladrius
    • Orphagen Pharmaceuticals Inc
    • Mimetogen Pharmaceuticals Inc
    • InFlectis BioScience
簡介目錄
Product Code: VMR11212336

The Retinitis Pigmentosa Treatment Market size is expected to reach USD 25.28 Billion in 2034 from USD 14.14 Billion (2025) growing at a CAGR of 6.67% during 2026-2034.

The global retinitis pigmentosa treatment market has been gaining attention as research advances in the management of this rare genetic eye disorder. Retinitis pigmentosa gradually damages the retina, leading to progressive vision loss. Growing awareness about rare diseases and improved diagnostic techniques have helped identify more patients, encouraging healthcare providers and researchers to focus on developing effective treatment solutions.

Several factors are driving the development of the retinitis pigmentosa treatment market. Increasing investments in genetic research and biotechnology have supported the exploration of gene therapies and advanced treatment options. Additionally, government support for rare disease research and collaborations between pharmaceutical companies and research institutions are accelerating the development of innovative therapies for retinal disorders.

Looking ahead, the market is expected to grow as scientific advancements lead to improved treatment approaches. Emerging technologies such as gene editing, stem cell therapy, and retinal implants may provide new possibilities for managing or slowing disease progression. As research continues and clinical trials expand, the retinitis pigmentosa treatment market is likely to see significant progress in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Autosomal Recessive
  • Autosomal Dominant
  • X-Linked

By Treatment

  • Drugs
  • Devices
  • Surgery

By Route of Administration

  • Oral
  • Topical
  • Others

By End- User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Ophthalmologist
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Johnson Johnson Services Inc, Astellas Pharma Inc, Ionis Pharmaceuticals Inc, MeiraGTx Limited, Agtc, Spark Therapeutics Inc, Genethon, GenSight Biologics, ProQR Therapeutics, ReNeuron Group plc, Ocugen Inc, Caladrius, Orphagen Pharmaceuticals Inc, Mimetogen Pharmaceuticals Inc, InFlectis BioScience
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL RETINITIS PIGMENTOSA TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Autosomal Recessive Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Autosomal Dominant Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. X-Linked Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RETINITIS PIGMENTOSA TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Treatment
  • 5.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RETINITIS PIGMENTOSA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RETINITIS PIGMENTOSA TREATMENT MARKET: BY END- USER 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End- User
  • 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Ophthalmologist Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL RETINITIS PIGMENTOSA TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL RETINITIS PIGMENTOSA TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Type
    • 9.2.2 By Treatment
    • 9.2.3 By Route Of Administration
    • 9.2.4 By End- User
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Type
    • 9.3.2 By Treatment
    • 9.3.3 By Route Of Administration
    • 9.3.4 By End- User
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Type
    • 9.4.2 By Treatment
    • 9.4.3 By Route Of Administration
    • 9.4.4 By End- User
    • 9.4.5 By Distribution Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Type
    • 9.5.2 By Treatment
    • 9.5.3 By Route Of Administration
    • 9.5.4 By End- User
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Type
    • 9.6.2 By Treatment
    • 9.6.3 By Route Of Administration
    • 9.6.4 By End- User
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL RETINITIS PIGMENTOSA TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Johnson & Johnson Services Inc
    • 11.2.2 Astellas Pharma Inc
    • 11.2.3 Ionis Pharmaceuticals Inc
    • 11.2.4 MeiraGTx Limited
    • 11.2.5 Agtc
    • 11.2.6 Spark Therapeutics Inc
    • 11.2.7 Genethon
    • 11.2.8 GenSight Biologics
    • 11.2.9 ProQR Therapeutics
    • 11.2.10 ReNeuron Group Plc
    • 11.2.11 Ocugen Inc
    • 11.2.12 Caladrius
    • 11.2.13 Orphagen Pharmaceuticals Inc
    • 11.2.14 Mimetogen Pharmaceuticals Inc
    • 11.2.15 InFlectis BioScience